Announcements Trials
Browse Landscape

Status

Completed 11Unknown 3Not yet recruiting 3Recruiting 2Terminated 1Enrolling by invitation 1

Sponsor Class

OTHER 1

Study Type

Interventional 65Observational 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1

Interventions

Blood Specimen Collection 27Surveys and Questionnaires 24Magnetic Resonance Spectroscopy 10Observation 7Flow Cytometry 7Specimen Handling 6Amplified Fragment Length Polymorphism Analysis 6exemestane 5Radiotherapy 5Magnetic Resonance Imaging 5Immunoenzyme Techniques 5Biopsy 5Radiation 4Neoadjuvant Therapy 4Mental Status and Dementia Tests 4Genetic Testing 4Gene Expression Profiling 4Electroporation 4Data Collection 4Bevacizumab 4Trastuzumab 3Tomography, X-Ray Computed 3Tomography, Optical Coherence 3Therapeutics 3Surgical Procedures, Operative 3Sunitinib 3Sorafenib 3Registries 3Radiosurgery 3Psychiatric Rehabilitation 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Observational × Imatinib Mesylate × Clear all
NCT02146846 2016-09-07

Population Pharmacokinetics of Imatinib in CML Patients in Iran

Kerman University of Medical Sciences

Terminated
170 enrolled
MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Data powered by HemOnc (CC BY 4.0) Colophon âš¡